Life Science Brunch with Euronext

This presentation will go over the different aspects of the financial journey of biotechnology companies when going through an IPO process. Oliver Schacht, PhD, CEO of Curetis N.V., has extensive experience in developing and implementing commercial strategies and financing measures (including IPOs), as well as in finance, M&A transactions and alliance negotiations. He has been the CEO of Curetis N.V. since 2011, was a co-founder and CFO of Epigenomics AG in Berlin and CEO of the US subsidiary Epigenomics Inc. (Seattle, USA).

Introduction by : Sebastian Grabert, Director – Representative for Germany,  Euronext